Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.

Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M, Maegel L, Mitsialis SA, Rog-Zielinska EA, Kourembanas S, Jonigk D, Hansmann G.

Sci Transl Med. 2018 Apr 25;10(438). pii: eaao0303. doi: 10.1126/scitranslmed.aao0303.

PMID:
29695452
2.

Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Christou H, Hudalla H, Michael Z, Filatava EJ, Li J, Zhu M, Possomato-Vieira JS, Dias-Junior C, Kourembanas S, Khalil RA.

J Pharmacol Exp Ther. 2018 Feb;364(2):258-274. doi: 10.1124/jpet.117.244798. Epub 2017 Dec 6.

PMID:
29212831
3.

Reply to Muraca et al.: Exosome Treatment of Bronchopulmonary Dysplasia: How Pure Should Your Exosome Preparation Be?

Mitsialis SA, Willis GR, Fernandez-Gonzalez A, Kourembanas S.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):970. doi: 10.1164/rccm.201710-2066LE. No abstract available.

PMID:
29160730
4.

Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency.

Willis GR, Kourembanas S, Mitsialis SA.

Front Cardiovasc Med. 2017 Oct 9;4:63. doi: 10.3389/fcvm.2017.00063. eCollection 2017.

5.

"Good things come in small packages": application of exosome-based therapeutics in neonatal lung injury.

Willis GR, Mitsialis SA, Kourembanas S.

Pediatr Res. 2018 Jan;83(1-2):298-307. doi: 10.1038/pr.2017.256. Epub 2017 Nov 22. Review.

6.

Can We Cure Bronchopulmonary Dysplasia?

Thébaud B, Kourembanas S.

J Pediatr. 2017 Dec;191:12-14. doi: 10.1016/j.jpeds.2017.07.028. Epub 2017 Sep 21. No abstract available.

PMID:
28942897
7.

Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.

Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, Kwong A, Mitsialis SA, Kourembanas S.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):104-116. doi: 10.1164/rccm.201705-0925OC.

PMID:
28853608
8.

Therapeutic Applications of Extracellular Vesicles: Perspectives from Newborn Medicine.

Willis GR, Kourembanas S, Mitsialis SA.

Methods Mol Biol. 2017;1660:409-432. doi: 10.1007/978-1-4939-7253-1_34. Review.

PMID:
28828676
9.

Stem cell-based therapies for the newborn lung and brain: Possibilities and challenges.

Mitsialis SA, Kourembanas S.

Semin Perinatol. 2016 Apr;40(3):138-51. doi: 10.1053/j.semperi.2015.12.002. Epub 2016 Jan 15. Review.

10.

Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice.

Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner DE, Coffey A, Antunes M, Robinson KL, Mitsialis SA, Kourembanas S, Thane K, Hoffman AM, McKenna DH, Rocco PR, Weiss DJ.

Stem Cells Transl Med. 2015 Nov;4(11):1302-16. doi: 10.5966/sctm.2014-0280. Epub 2015 Sep 16.

11.

The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up.

Vitali SH, Hansmann G, Rose C, Fernandez-Gonzalez A, Scheid A, Mitsialis SA, Kourembanas S.

Pulm Circ. 2014 Dec;4(4):619-29. doi: 10.1086/678508.

12.

Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy.

Kourembanas S.

Annu Rev Physiol. 2015;77:13-27. doi: 10.1146/annurev-physiol-021014-071641. Epub 2014 Sep 25. Review.

PMID:
25293529
13.

An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells.

Hale A, Lee C, Annis S, Min PK, Pande R, Creager MA, Julian CG, Moore LG, Mitsialis SA, Hwang SJ, Kourembanas S, Chan SY.

Biochim Biophys Acta. 2014 Nov;1843(11):2528-42. doi: 10.1016/j.bbamcr.2014.06.012. Epub 2014 Jun 28.

14.

Expanding the pool of stem cell therapy for lung growth and repair.

Kourembanas S.

Circulation. 2014 May 27;129(21):2091-3. doi: 10.1161/CIRCULATIONAHA.114.009727. Epub 2014 Apr 7. No abstract available.

15.

Stem cell-based therapy for newborn lung and brain injury: feasible, safe, and the next therapeutic breakthrough?

Kourembanas S.

J Pediatr. 2014 May;164(5):954-6. doi: 10.1016/j.jpeds.2014.01.064. Epub 2014 Mar 12. No abstract available.

PMID:
24630358
16.

MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy.

Sdrimas K, Kourembanas S.

Antioxid Redox Signal. 2014 Nov 1;21(13):1905-15. doi: 10.1089/ars.2013.5784. Epub 2014 Feb 24. Review.

17.

Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension.

Xiao Y, Christou H, Liu L, Visner G, Mitsialis SA, Kourembanas S, Liu H.

Am J Respir Crit Care Med. 2013 Aug 15;188(4):482-91. doi: 10.1164/rccm.201304-0700OC.

18.

Diffuse lung disease in children: summary of a scientific conference.

Hamvas A, Deterding R, Balch WE, Schwartz DA, Albertine KH, Whitsett JA, Cardoso WV, Kotton DN, Kourembanas S, Hagood JS.

Pediatr Pulmonol. 2014 Apr;49(4):400-9. doi: 10.1002/ppul.22805. Epub 2013 Jun 24.

19.

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, Hare JM, Hei DJ, Hoffman AM, Kourembanas S, McKenna DH, Ortiz LA, Ott HC, Tente W, Thébaud B, Trapnell BC, Weiss DJ, Yuan JX, Blaisdell CJ.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):370-5. doi: 10.1164/rccm.201303-0522WS. Review.

20.

Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.

Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, Sdrimas K, Fernandez-Gonzalez A, Kourembanas S.

Circulation. 2012 Nov 27;126(22):2601-11. doi: 10.1161/CIRCULATIONAHA.112.114173. Epub 2012 Oct 31.

21.

Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension.

Hansmann G, Fernandez-Gonzalez A, Aslam M, Vitali SH, Martin T, Mitsialis SA, Kourembanas S.

Pulm Circ. 2012 Apr-Jun;2(2):170-81. doi: 10.4103/2045-8932.97603.

22.

Perinatal stress, brain inflammation and risk of autism-review and proposal.

Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theoharides TC.

BMC Pediatr. 2012 Jul 2;12:89. doi: 10.1186/1471-2431-12-89. Review.

23.

Regenerative pulmonary medicine: potential and promise, pitfalls and challenges.

Anversa P, Perrella MA, Kourembanas S, Choi AM, Loscalzo J.

Eur J Clin Invest. 2012 Aug;42(8):900-13. doi: 10.1111/j.1365-2362.2012.02667.x. Epub 2012 Mar 21. Review.

24.

Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia.

Tropea KA, Leder E, Aslam M, Lau AN, Raiser DM, Lee JH, Balasubramaniam V, Fredenburgh LE, Alex Mitsialis S, Kourembanas S, Kim CF.

Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L829-37. doi: 10.1152/ajplung.00347.2011. Epub 2012 Feb 10.

25.

Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Christou H, Reslan OM, Mam V, Tanbe AF, Vitali SH, Touma M, Arons E, Mitsialis SA, Kourembanas S, Khalil RA.

Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L875-90. doi: 10.1152/ajplung.00293.2011. Epub 2012 Jan 27.

26.

Vasculoprotective effects of heme oxygenase-1 in a murine model of hyperoxia-induced bronchopulmonary dysplasia.

Fernandez-Gonzalez A, Alex Mitsialis S, Liu X, Kourembanas S.

Am J Physiol Lung Cell Mol Physiol. 2012 Apr 15;302(8):L775-84. doi: 10.1152/ajplung.00196.2011. Epub 2012 Jan 27.

27.

Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Vergadi E, Chang MS, Lee C, Liang OD, Liu X, Fernandez-Gonzalez A, Mitsialis SA, Kourembanas S.

Circulation. 2011 May 10;123(18):1986-95. doi: 10.1161/CIRCULATIONAHA.110.978627. Epub 2011 Apr 25.

28.

Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension.

Liang OD, Mitsialis SA, Chang MS, Vergadi E, Lee C, Aslam M, Fernandez-Gonzalez A, Liu X, Baveja R, Kourembanas S.

Stem Cells. 2011 Jan;29(1):99-107. doi: 10.1002/stem.548.

29.

In-house neonatology: what are we waiting for?

Kourembanas S, Steinhorn R.

Am J Respir Crit Care Med. 2010 Sep 15;182(6):728-9. doi: 10.1164/rccm.201006-0949ED. No abstract available.

PMID:
20833827
30.

Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease.

Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, Kourembanas S.

Am J Respir Crit Care Med. 2009 Dec 1;180(11):1122-30. doi: 10.1164/rccm.200902-0242OC. Epub 2009 Aug 27.

31.

Divergent cardiopulmonary actions of heme oxygenase enzymatic products in chronic hypoxia.

Vitali SH, Mitsialis SA, Liang OD, Liu X, Fernandez-Gonzalez A, Christou H, Wu X, McGowan FX, Kourembanas S.

PLoS One. 2009 Jun 19;4(6):e5978. doi: 10.1371/journal.pone.0005978.

32.

Mutation of murine adenylate kinase 7 underlies a primary ciliary dyskinesia phenotype.

Fernandez-Gonzalez A, Kourembanas S, Wyatt TA, Mitsialis SA.

Am J Respir Cell Mol Biol. 2009 Mar;40(3):305-13. doi: 10.1165/rcmb.2008-0102OC. Epub 2008 Sep 5.

33.

Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells.

Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, Riascos DF, Chung SW, Schissel SL, Ingber DE, Mitsialis SA, Kourembanas S, Perrella MA.

Circulation. 2008 Apr 22;117(16):2114-22. doi: 10.1161/CIRCULATIONAHA.107.716241. Epub 2008 Apr 7.

34.

Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1.

Wu X, Chang MS, Mitsialis SA, Kourembanas S.

Circ Res. 2006 Aug 4;99(3):240-7. Epub 2006 Jul 13.

PMID:
16840720
35.

Mechanisms of heme oxygenase-1-mediated cardiac and pulmonary vascular protection in chronic hypoxia: roles of carbon monoxide and bilirubin.

Vitali SH, Mitsialis SA, Christou H, Fernandez-Gonzalez A, Liu X, Kourembanas S.

Chest. 2005 Dec;128(6 Suppl):578S-579S. No abstract available.

PMID:
16373841
36.

Pulmonary hypertension and right ventricular dysfunction in growth-restricted, extremely low birth weight neonates.

Danhaive O, Margossian R, Geva T, Kourembanas S.

J Perinatol. 2005 Jul;25(7):495-9.

PMID:
15830004
37.

Extracellular acidosis induces heme oxygenase-1 expression in vascular smooth muscle cells.

Christou H, Bailey N, Kluger MS, Mitsialis SA, Kourembanas S.

Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2647-52. Epub 2005 Jan 28.

38.

Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/ p44 and PI3 kinase pathways.

Zampetaki A, Mitsialis SA, Pfeilschifter J, Kourembanas S.

FASEB J. 2004 Jul;18(10):1090-2. Epub 2004 May 7.

PMID:
15132979
39.

Effect of heme oxygenase-1 overexpression in two models of lung inflammation.

Zampetaki A, Minamino T, Mitsialis SA, Kourembanas S.

Exp Biol Med (Maywood). 2003 May;228(5):442-6.

PMID:
12709566
40.

Hypoxia and carbon monoxide in the vasculature.

Kourembanas S.

Antioxid Redox Signal. 2002 Apr;4(2):291-9. Review.

PMID:
12006180
41.

Mechanisms of telomerase induction during vascular smooth muscle cell proliferation.

Minamino T, Kourembanas S.

Circ Res. 2001 Aug 3;89(3):237-43.

PMID:
11485973
42.

Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia.

Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8798-803. Epub 2001 Jul 10.

43.
44.

Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation.

Minamino T, Mitsialis SA, Kourembanas S.

Mol Cell Biol. 2001 May;21(10):3336-42.

45.

Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn.

Christou H, Van Marter LJ, Wessel DL, Allred EN, Kane JW, Thompson JE, Stark AR, Kourembanas S.

Crit Care Med. 2000 Nov;28(11):3722-7.

PMID:
11098980
46.

Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat.

Christou H, Morita T, Hsieh CM, Koike H, Arkonac B, Perrella MA, Kourembanas S.

Circ Res. 2000 Jun 23;86(12):1224-9. Erratum in: Circ Res 2002 Mar 8;90(4):e66-a.

PMID:
10864912
47.

Generation of a dominant-negative mutant of endothelial PAS domain protein 1 by deletion of a potent C-terminal transactivation domain.

Maemura K, Hsieh CM, Jain MK, Fukumoto S, Layne MD, Liu Y, Kourembanas S, Yet SF, Perrella MA, Lee ME.

J Biol Chem. 1999 Oct 29;274(44):31565-70.

48.

Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice.

Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, Lee ME.

J Clin Invest. 1999 Apr;103(8):R23-9.

49.

Inhaled nitric oxide does not affect adenosine 5'-diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn.

Christou H, Magnani B, Morse DS, Allred EN, Van Marter LJ, Wessel DL, Kourembanas S.

Pediatrics. 1998 Dec;102(6):1390-3.

PMID:
9832574
50.

Hypoxic responses of vascular cells.

Kourembanas S, Morita T, Christou H, Liu Y, Koike H, Brodsky D, Arthur V, Mitsial SA.

Chest. 1998 Jul;114(1 Suppl):25S-28S. Review. No abstract available.

PMID:
9676610

Supplemental Content

Loading ...
Support Center